- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Research progress of antibody–drug conjugates in gynecologic cancer ; volume:3 ; number:1 ; day:29 ; month:8 ; year:2024 ; pages:1-13 ; date:12.2024
Holistic integrative oncology ; 3, Heft 1 (29.8.2024), 1-13, 12.2024
- Creator
-
Xu, Dongdong
Chen, Zhe-Sheng
Peng, Xuanwei
Lin, Zhongqiu
Lu, Huaiwu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s44178-024-00114-8
- URN
-
urn:nbn:de:101:1-2411250841299.414798966992
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Xu, Dongdong
- Chen, Zhe-Sheng
- Peng, Xuanwei
- Lin, Zhongqiu
- Lu, Huaiwu
- SpringerLink (Online service)
Other Objects (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates as an emerging therapy in oncodermatology
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates